Parkinson disease and incidental Lewy body disease: Just a question of time?

Neurology

Volumn 85, Issue 19, 2015, Pages 1670-1679

  Iacono, Diego ^a,b,c   Geraci Erck, Maria ^a   Rabin, Marcie L ^b   Adler, Charles H ^d   Serrano, Geidy ^e   Beach, Thomas G ^e   Kurlan, Roger ^b,c  

^a Biomedical Research Institute of New Jersey   (United States)

^b Overlook Medical Center   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

AGED; AMYLOID PLAQUE; ARTICLE; AUTOPSY; BRAIN INFARCTION SIZE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTAL CORTEX; GENE FREQUENCY; HUMAN; HUMAN TISSUE; INCIDENTAL LEWY BODY DISEASE; LEWY BODY; MALE; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; OLFACTORY BULB; PARIETAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; STEREOLOGY; SUBSTANTIA NIGRA; TEMPORAL CORTEX; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY; LONGITUDINAL STUDY; NERVE CELL; PATHOLOGY; TIME FACTOR;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEWY BODY DISEASE; LONGITUDINAL STUDIES; MALE; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 84946923292     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002102     Document Type: Article

References (40)

1. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8-30.
2. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055-2066.
3. Seidel K, Mahlke J, Siswanto S, et al. The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. Brain Pathol 2015;25:121-135.
4. Oyanagi K, Tsuchiya K, Yamazaki M, et al. Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features. J Neuropathol Exp Neurol 2001;60:393-402.
5. Buchman AS, Shulman JM, Nag S, et al. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 2012;71:258-266.
6. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
7. Beach TG, Adler CH, Lue L, et al; Arizona Parkinson's Disease Consortium. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009; 117:613-634.
8. Halliday GM, McCann H. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms. Exp Neurol 2008;209:12-21.
9. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.
10. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997;38(suppl 2):2-7.
11. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012;27:709-715.
12. Bloch A, Probst A, Bissig H, et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006;32:284-295.
13. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014;29:1010-1018.
14. Ben-Shlomo Y, Wenning G. Incidental Lewy body disease. Lancet 1994;344:1503.
15. Adler CH, Connor DJ, Hentz JG, et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord 2010;25:642-646.
16. Frigerio R, Fujishiro H, Ahn TB, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 2011;32:857-863.
17. Delle Donne A, Klos KJ, Fujishiro H, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008;65:1074-1080.
18. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004;111:1219-1235.
19. Beach TG, Adler CH, Sue LI, et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 2008;115:445-451.
20. Milber JM, Noorigian JV, Morley JF, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 2012;79:2307-2314.
21. Ross GW, Petrovitch H, Abbott RD, et al. Parkinsonian signs and substantia nigra neuron density in descendants elders without PD. Ann Neurol 2004;56:532-539.
22. Beach TG, Sue LI, Walker DG, et al. The sun health research Institute brain donation program: description and experience, 1987-2007. Cell Tissue Bank 2008;9:229-245.
23. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
24. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991;1:213-216.
25. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150-1157.
26. Fahn S, Marsden CD, Calne DB, Goldstein M, et al. Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153-163.
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
28. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
29. The National Institute on Aging, and Reagan Institute Working group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's disease Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18:S1-S2.
30. Gundersen HJ, Bagger P, Bendtsen TF, et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988;96:857-881.
31. Rudow G, O'Brien R, Savonenko AV, et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol 2008;115:461-470.
32. Richard IH, Papka M, Rubio A, et al. Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov Disord 2002;17:1161-1165.
33. Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord 2013;28:31-40.
34. Dickson DW, Fujishiro H, Delle Donne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008;115:437-444.
35. Kurlan R. Do Parkinson's disease and dementia with Lewy bodies differ by route of environmental precipitant? Mov Disord 2008;23:1617.
36. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary agerelated tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014;128:755-766.
37. Driver-Dunckley E, Adler CH, Hentz JG, et al. Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. Parkinsonism Relat Disord 2014;20:1260-1262.
38. Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999;58: 120-129.
39. Colosimo C, Hughes AJ, Kilford L, et al. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74:852-856.
40. Ferrer I, Martinez A, Blanco R, et al. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 2011;118:821-839.